Digital Health News | pharmaphorum

News

Veeva buys brand engagement firm Ostro for $100m

Veeva Systems has reached a $100m deal to acquire Ostro, which helps pharma connect with doctors and patients using AI-based conversational tools.

News

Lundbeck names AI head in quest to become 'bionic' company

Lundbeck has appointed Markus Kede to the newly created role of chief AI officer, charged with driving its ambition to become a 'bionic' company.

News

Novo partners with Hims & Hers again, ending GLP-1 spat

Novo Nordisk and Hims & Hers have set their differences aside, agreeing to work together once again on the sale of GLP-1 agonists.

News

Man on his smartphone while sitting on sifa

Daiichi teams up with GAIA for cholesterol DTx in Europe

Daiichi Sankyo has licensed European rights to GAIA's digital therapeutic for people with high cholesterol, currently in phase 3 testing.

News

Pinky promise made by stone statue hands

Alnylam bets on Tenaya RNAi tech, and other licensing news

This week's round-up of pharma licensing deals features alliances involving Tenaya Therapeutics, Sino Bio, Antengene, and A2A Pharma.

News

Welsh firm Antiverse raises funds for AI antibody platform

Cardiff's Antiverse has raised $9.3m to develop its AI-based design platform for antibodies against hard-to-reach targets like GPCRs and ion channels.

Veeva buys brand engagement firm Ostro for $100m

Lundbeck names AI head in quest to become 'bionic' company

Novo partners with Hims & Hers again, ending GLP-1 spat

Daiichi teams up with GAIA for cholesterol DTx in Europe

Alnylam bets on Tenaya RNAi tech, and other licensing news

Welsh firm Antiverse raises funds for AI antibody platform

LSX2026: On promise and patience, with Hans Schambye

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks